Ependymoma is a tumor of mesenchymal origin. There are no benign tumors in this category, and there are two grades II and III, which require postoperative radiotherapy. I still remember the previous month in the director’s clinic, a girl in her 20s with fornix occupancy at the top of the frontal fornix experienced a long time in the first surgery and a lot of blood, but the tumor was only partially removed. The first feature of this tumor is the difficulty of surgery and bleeding; the second feature is the difficulty of total resection and easy recurrence, just like Dr. Yuan’s patient who had already undergone 4 surgeries and now recurred; the third feature is unique to extravascular meningioblastoma, that is, it is easy to metastasize outside of the skull, and metastasis has occurred in lung, liver, bone and other parts. The third feature is unique to hemangiopericytoma, which is prone to extracranial metastasis. I spent half a day searching the NIH resources for treatment advances and was surprised to find that this tumor actually belongs to the research gap. Basically, it was all about surgery and some clinical features of recurrence, but of course we also studied more than 40 cases of recurrent angioepithelial cell tumors, and there were very few clinical trials related to chemotherapy. As a neurosurgeon, I know that sometimes surgeons can cure diseases, but more often new treatments guided by scientific research are needed to achieve them.